• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4170.TWO
Share

VBI Stocks

NT$ 12.5Last Updated 29.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

NT$ 19.37M

NT$ 12.5
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Vectorite Biomedical Inc., established in 1993 and based in New Taipei City, Taiwan, is a biotechnology firm dedicated to research and development activities globally, including a strong presence in its home country. The company's operations encompass the manufacturing of specialized cell preparation products, in addition to providing full-spectrum services for the collection, processing, and secure storage management of immune cells. These advanced cellular preparations are vital for applications in the medical fields of infectious diseases, inflammatory conditions, and various oncological and tumor-related illnesses.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 15:00

IPO Reformation: The Brand That Dressed Taylor Swift and Jennifer Aniston Goes Public

30.07.2026 14:59

Jersey Mike’s IPO: Shares of the sandwich bar chain challenging Subway are now available

30.07.2026 14:34

Central banks sharply reduced their gold purchases in early 2026—to a 15-year low

30.07.2026 13:50

Qualcomm's stock fell 5% due to a weak outlook and a rapid loss of orders from Apple

30.07.2026 12:36

A tanker carrying cargo for a Chevron subsidiary was attacked by drones in the Black Sea

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026